These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30819188)

  • 21. Insulin resistance: Impact on therapeutic developments in diabetes.
    Bailey CJ
    Diab Vasc Dis Res; 2019 Mar; 16(2):128-132. PubMed ID: 31014100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study.
    Torre C; Guerreiro J; Longo P; Raposo JF; Leufkens H; Martins AP
    Prim Care Diabetes; 2019 Jun; 13(3):221-232. PubMed ID: 30573348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular outcome trials of glucose-lowering medications: an update.
    Home P
    Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
    Sukkar L; Young T; Jardine MJ
    Kidney Blood Press Res; 2020; 45(6):823-836. PubMed ID: 33271545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New anti-diabetic agents: major advances with unanswered questions.
    Sabouret P; Bocchino PP; Biondi-Zoccai G
    Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study.
    Pintaudi B; Scatena A; Piscitelli G; Frison V; Corrao S; Manicardi V; Graziano G; Rossi MC; Gallo M; Mannino D; Di Bartolo P; Nicolucci A
    Cardiovasc Diabetol; 2021 Mar; 20(1):59. PubMed ID: 33676499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antidiabetic drugs and blood pressure changes.
    Ilias I; Thomopoulos C; Michalopoulou H; Bazoukis G; Tsioufis C; Makris T
    Pharmacol Res; 2020 Nov; 161():105108. PubMed ID: 32738493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
    van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
    Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
    Mosenzon O; Del Prato S; Schechter M; Leiter LA; Ceriello A; DeFronzo RA; Raz I
    Cardiovasc Diabetol; 2021 Apr; 20(1):92. PubMed ID: 33910583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.
    León Jiménez D; Cherney DZI; Bjornstad P; Castilla-Guerra L; Miramontes González JP
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1406-F1415. PubMed ID: 30066584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
    Cefalo CMA; Cinti F; Moffa S; Impronta F; Sorice GP; Mezza T; Pontecorvi A; Giaccari A
    Cardiovasc Diabetol; 2019 Feb; 18(1):20. PubMed ID: 30819210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
    Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
    Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.
    Fiorentino TV; Sesti G
    Endocrine; 2016 Aug; 53(2):373-80. PubMed ID: 26611248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular safety outcomes of new antidiabetic therapies.
    LeBras MH; Barry AR; Koshman SL
    Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB
    Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dipeptidyl peptidase-4 inhibitor approaches.
    Bloomgarden Z
    J Diabetes; 2017 Jan; 9(1):5-7. PubMed ID: 27576300
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.